PolymarketVerfügbarkeit prüfenKein KYCVerifizierte AuflösungsdatenGut kalibriertWarnung zur DatenqualitätKeine aktiven Kurse
Daten vom 05.10.2026, 22:11 UTC · Richtlinie pm-quality-4
Aktuelle implizite Wahrscheinlichkeit
June 30, 83%
June 30, 83%Marktqualitat
≤49 / 100
Niedrige Qualität24h-Volumen
—
Liquidität
6982,4 €
Mittlere LiquiditätGeld / Brief
82.0% / 83.0%
Spread
1.0 pt
Enger SpreadKommentare
0
Marktdaten
Aktualisiert vor 5 Minuten
19. Aug. 26, 18:47 UTC1. Juli 27, 03:59 UTC
Trends
Handelsplatzbedingungen
Quelle: Polymarket
Diese Angaben dienen der Information; für den simulierten Handel bei CoinRithm gelten eigene Regeln.
- Mindestorder (Anteile):
- 5
- Preisschritt:
- 1 Prozentpunkte
- Gebühren:
- Ja
Verwandte Märkte
Verwandte Fragen als Kontext, kein Vergleich gleichwertiger Kontrakte.
FDA approves skin cancer vaccine by which date?
PolymarketIs Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsWill the Russian cancer vaccine work?
Manifold MarketsIs Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsWhat will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Manifold MarketsWill CDC cut the childhood vaccine schedule below 11 diseases in 2026?
KalshiRegeln
This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET.
- Otherwise, this market will resolve to "No".
- Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
- A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA).
- An original BLA or a resubmission of such a BLA following FDA action will qualify.
- The application may cover any indication.